12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Veltuzumab: Phase II discontinued

Immunomedics said in its 1Q13 earnings ending Sept. 30 that Takeda's Nycomed unit discontinued the Phase II VELVET trial of veltuzumab and will "redesign the study protocol and start a new trial as soon as possible." Immunomedics said that in November 2011 enrollment was discontinued in the double-blind, placebo-controlled, international VELVET trial,...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >